Heron Therapeutics | HRTX - Equity Capital And Reserves


Heron Therapeutics reported $9.14M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
ALKERMES USD 1.75B 67.76M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amarin USD 449.41M 9.87M Mar/2026
ANI Pharmaceuticals USD 562.3M 21.58M Mar/2026
Anika Therapeutics USD 133.9M 9.56M Mar/2026
Arrowhead Research USD 613.98M 45.56M Mar/2026
Eisai JPY 898.99B 9.36B Mar/2026
Emergent BioSolutions USD 649.3M 47.9M Dec/2023
Esperion Therapeutics USD -307.93M 5.97M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Insmed USD 704.85M 34.12M Mar/2026
Ligand Pharmaceuticals USD 997.32M 19.89M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Omeros USD -228.68M 15.13M Jun/2025
Pacira USD 653.89M 39.22M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Surmodics USD 111.31M 7.59M Jun/2025
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Veracyte USD 1.34B 34.83M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026